Goldman upgrades Biogen, says it’s poised to address early Alzheimer’s market next year
Biogen shares have a lot more potential upside thanks to positive new data around the company's early Alzheimer's drug, Goldman Sachs said Wednesday.
LocalNews
0
56
Biogen shares have a lot more potential upside thanks to positive new data around the company's early Alzheimer's drug, Goldman Sachs said Wednesday.
